作为结直肠癌治疗的目标,PI3K/Akt/mTOR信号通路是结直肠癌治疗的目标
Premila D Leiphrakpam1,2, Chandrakanth Are1,2
1Graduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
International journal of molecular sciences
|March 28, 2024
概括
向疗法已在结直肠癌 (CRC) 治疗中取得了先进的进展,但耐药性需要了解PI3K/Akt/mTOR等分子途径. 这次审查探讨了PI3K/Akt/mTOR.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 特定途径的向疗法已经改变了结直肠癌 (CRC) 治疗.
- 在CRC中瘤异质性往往导致治疗耐药性.
- 拉巴胺素 (PI3K/Akt/mTOR) 途径的酸3-激酶/蛋白激酶B/哺乳动物点在CRC中经常发生变化.
研究的目的:
- 审查PI3K/Akt/mTOR信号通路在CRC中的作用.
- 讨论目前用于治疗CRC的PI3K/Akt/mTOR向剂.
- 突出限制和未来的方向,针对CRC的这一途径.
主要方法:
- 对CRC中的PI3K/Akt/mTOR信号研究的文献综述.
- 对CRC中PI3K/Akt/mTOR抑制剂的临床试验数据的分析.
- 综合关于CRC分子机制和向治疗的信息.
主要成果:
- 异常的PI3K/Akt/mTOR激活驱动CRC的启动,进展和转移.
- 这一途径对于CRC中药物耐药性的发展至关重要.
- 一些针对PI3K/Akt/mTOR的药物正在进行CRC的临床试验.
结论:
- 了解PI3K/Akt/mTOR信号对于克服CRC治疗耐药性至关重要.
- 针对PI3K/Akt/mTOR途径为新型CRC疗法提供了潜力.
- 需要进一步的研究来优化PI3K/Akt/mTOR向药物和CRC的组合策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


